Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-12-22 00:00:00 ET · period of report 2023-12-20 · accession 0001610717-23-000419 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-22 | 2023-12-20 | CTMX | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $1.38 | -1,990 | 48.7K | -4% | -$2,746 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-20 | S | D | 1,990 | $1.38 | 48,657 | D | — | — | (F2) Includes 30,466 restricted stock units. |